Yevgeniy Skaradinskiy
Hematology & Oncology · Bronx, NYNPI 1467646661
Payments from drug & device makers
Across 21 payments — averaging $33.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novocure GmbH$200
- Johnson & Johnson$81
- Eisai Inc.$76
- Takeda Pharmaceuticals U.S.A., Inc.$59
- AstraZeneca$55
- Regeneron Healthcare Solutions, Inc.$51
- plus $184 from 7 others
What the payments were for
- Speaking & faculty fees$20028%
- Food & beverage$45564%
- Education$517%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novocure GmbH | 1 | $200 |
| Johnson & Johnson | 3 | $81 |
| Eisai Inc. | 3 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $59 |
| AstraZeneca(2 entities) | 2 | $55 |
| Regeneron Healthcare Solutions, Inc. | 3 | $51 |
| Deciphera Pharmaceuticals Inc. | 1 | $33 |
| Agios Pharmaceuticals, Inc. | 1 | $33 |
| Nuvation Bio Inc. | 1 | $31 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Boston Scientific | 1 | $23 |
| Boehringer Ingelheim | 1 | $22 |
| Merck | 1 | $17 |
How this compares
$706 in reported general payments places this provider in the 30th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 31 | $426,459 |
| NubeqaDarolutamide | 11 | $150,884 |
| Imatinib Mesylate | 23 | $22,630 |
| EliquisApixaban | 13 | $13,475 |
| Aprepitant | 16 | $5,504 |
| Prochlorperazine Maleate | 11 | $667 |
| Bicalutamide | 20 | $493 |
| Hydroxyurea | 19 | $300 |
| Anastrozole | 27 | $291 |
| Ondansetron Hcl | 34 | $251 |
| Prednisone | 11 | $14 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Bronx
- Vicky MakkerNew York$27.1M
- Alison MoskowitzNew York$22.7M
- Ajai ChariNew York$22.4M
- Yelena JanjigianNew York$16.9M
- Alexander LesokhinNew York$11.9M
- John MascarenhasNew York$11.8M
- Maria PalombaNew York$11.6M
- Richard ZunigaBabylon$10.9M
- Scott TagawaNew York$10.3M
- Mohammad Abdul HayNew York$9.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.